Pharma giant Roche has joined forces with Domo Health to develop a digital health solution to predict respiratory failure in patients suffering from spinal muscular atrophy. The launched clinical trial is anticipated to end mid-2023.
The adoption of new digital health technologies is accelerating globally. Thanks to digital health solutions, it is now possible to monitor the progression of a disease in a comprehensive, continuous and clinical-grade manner. In cases of spinal muscular atrophy (SMA), a rare neuromuscular disease, patients are often physically limited and obliged to use a wheelchair. With such a loss of autonomy, an emergency can quickly have dramatic consequences.
Domo Health has developed, and patented Artificial Intelligence based data platform to collect, process and analyze patient data to enable healthcare workers to detect and predict sudden deteriorations in illness. The underlying algorithms are the result of analyses of billions of physiological and behavioural data points.
In collaboration with Roche Pharma Suisse SA, the patient association SMA Schweiz, CHUV and Inselspital, Domo Health has launched a clinical study to develop digital biomarkers to detect hypoventilation and warning signs of respiratory infections. The solution will benefit patients suffering from spinal muscular atrophy. The results of the study are expected for the 2nd quarter of 2023.
By combining a home alert system, clinical expertise and real-time health data, the Domo Health platform can detect the first signs of illness and caregivers, the emergency centre and doctors are directly alerted. Therefore, care is provided as quickly as possible, wherever the patient is. A solution that can save lives in an emergency situation.
Guillaume DuPasquier, CEO and co-founder of Domo Health, comments: “Our universal digital health platform has the potential to revolutionize the management and monitoring of patients on a daily basis. In the context of this study, the application of our innovative method will improve the independence and quality of life of patients with severe neuromuscular disease.”
Anne Marquet, SMA Rare Conditions Partner at Roche in Switzerland, adds: “We are confident and looking forward to the first results of the study and to continue our collaboration with the entire SMA community and develop together new solutions to improve the daily lives of people living with this rare disease.”
(Press release/RAN)
Please login or sign up to comment.
Commenting guidelines